Resolve M exits stealth with a bold MS1-based approach to inflammation. Learn how its pro-resolution platform could reshape autoimmune drug development.
Will Gr-ADI fix the broken antibiotic pipeline? Explore how Gates, Novo, and Wellcome aim to reboot AMR innovation with $60M in global grants.
BTL’s EMFACE wins global IP battle against WonderFace. Find out how this reshapes the energy-based facial therapy market in 2026.
Doctors Studio’s ozone pilot shows promising 30-day shifts in prostate biomarkers tracked via EpiSwitch PSE. Could this reshape trial design? Find out.
Avacta Therapeutics (LSE: AVCT) has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration for AVA6103 (also known as FAP-Exd), its second clinical-stage asset developed using the company’s proprietary pre|CISION platform. The IND clearance enables the start of a Phase 1 trial evaluating the safety, tolerability, and dose parameters of
Can a feeding tube that monitors vitals change neonatal care? See why Neotech is backing this multifunctional device startup.
Insilico’s AI-designed drug ISM8969 enters Phase 1 for Parkinson’s disease. Find out what this NLRP3 candidate could mean for CNS drug development.
See how RELiZORB improved weight and BMI z-scores in tube-fed children aged 1–5 in new real-world data. Explore what this means for pediatric care today.
FDA clears Flowflex Plus 4-in-1 test for RSV, flu, and COVID in infants and adults. Find out what this means for diagnostics, families, and industry players.
Sarepta’s EMBARK 3-year readout could clarify ELEVIDYS’ long-term role in Duchenne care. Find out what’s at stake in this pivotal gene therapy trial.